Merck and Moderna have announced promising results from a Phase 3 trial of a personalized mRNA cancer vaccine used in conjunction with Keytruda for melanoma treatment. The trial, involving 1,137 patients, showed a 42% reduction in the risk of melanoma recurrence or death. Two-year survival rates without recurrence were 82.2% for those receiving the vaccine, compared to 70% for those on Keytruda alone. Experts noted the need for further research and logistical planning for large-scale treatment implementation.
Key facts
- Merck and Moderna conducted a Phase 3 trial with 1,137 melanoma patients.
- The vaccine reduced melanoma recurrence risk by 42% compared to Keytruda alone.
- 82.2% of patients receiving the vaccine were alive without recurrence after two years.
- The combination therapy reduced the risk of cancer spreading or death by 38%.
- Regulatory approval is being sought by Merck for the personalized vaccine.
A short AI summary in our own words. The reporting belongs to Daily Wire; we don't reproduce it.